Healthcare / Drug Manufacturers - Specialty & GenericASX
$3.25
+0.03 (+0.93%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $6.2M · quality 44.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$341M
P/E
27.1x
↑EV/EBITDA
13.8x
↑ROE
13.4%
↑Gross Margin
42.6%
↓Debt/Equity
0.49
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+17.3%
FCF CAGR
—
FCF margin
-7.7%
FCF / Net income
-1.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $251.2M · net income $14.7M · FCF $-19.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $251.2M | $251.2M | $205.5M | $194.0M | $155.8M |
| Net Income | $14.7M | $14.7M | $12.0M | $15.6M | $10.7M |
| EBITDA | $27.8M | $27.8M | $21.2M | $27.4M | $20.2M |
| EPS | — | — | 0.11 | 0.15 | 0.10 |
| Gross Margin | 42.6% | 42.6% | 43.4% | 44.8% | 46.3% |
| Operating Margin | 6.9% | 6.9% | 5.7% | 10.5% | 11.0% |
| Net Margin | 5.9% | 5.9% | 5.8% | 8.0% | 6.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.49 | 0.49 | 0.31 | 0.37 | 0.52 |
| Current Ratio | 2.24 | 2.24 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-19.3M | $-19.3M | $6.2M | $19.3M | $2.5M |
| Returns | |||||
| ROE | 13.4% | 13.4% | 12.3% | 17.8% | 14.5% |
| Valuation | |||||
| P/E | 27.08 | 27.08 | 20.91 | 20.00 | 32.00 |
| EV/EBITDA | 13.84 | 13.84 | 12.24 | 12.21 | 18.29 |
| P/B | 3.09 | 3.09 | 2.47 | 3.58 | 4.58 |
| Growth & Yield | |||||
| Revenue Growth | 22.2% | 22.2% | 5.9% | 24.5% | — |
| EPS Growth | — | — | -26.7% | 50.0% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+30.5%
Start / end P/E
n/dx → n/dx
EPS bridge
0.11 → n/d
Residual
+30.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.